← Back to Screener
Seres Therapeutics, Inc. (MCRB)
Price$8.89
Favorite Metrics
Price vs S&P 500 (26W)-62.25%
Price vs S&P 500 (4W)-4.91%
Market Capitalization$85.22M
P/E Ratio (Annual)14.96x
All Metrics
P/CF (Annual)76.30x
Book Value / Share (Quarterly)$4.63
P/TBV (Annual)13.79x
Indicated Dividend (Annual)$0.00
Revenue Growth (3Y)-71.62%
Cash Flow / Share (Quarterly)$0.09
Price vs S&P 500 (YTD)-44.39%
Net Profit Margin (TTM)-903.80%
EPS (TTM)$0.75
10-Day Avg Trading Volume0.04M
EPS Excl Extra (TTM)$0.75
Revenue Growth (5Y)-52.34%
EPS (Annual)$0.64
ROI (Annual)12.88%
Net Profit Margin (5Y Avg)-29.07%
Cash / Share (Quarterly)$4.79
P/E Basic Excl Extra (TTM)14.96x
P/E Normalized (Annual)14.96x
ROA (Last FY)4.12%
EBITD / Share (TTM)$0.86
ROE (5Y Avg)-481.38%
Operating Margin (TTM)-1715.46%
Cash Flow / Share (Annual)$0.09
P/B Ratio1.93x
P/B Ratio (Quarterly)3.04x
Net Income / Employee (Annual)$0
EV / Revenue (TTM)50.01x
Net Interest Coverage (TTM)-60.98x
ROA (TTM)3.86%
EPS Growth QoQ (YoY)60.81%
EV / EBITDA (TTM)5.19x
EPS Incl Extra (Annual)$0.64
Current Ratio (Annual)2.56x
Quick Ratio (Quarterly)2.40x
3-Month Avg Trading Volume0.07M
52-Week Price Return11.13%
EV / Free Cash Flow (Annual)45.61x
P/E Incl Extra (TTM)14.96x
Revenue / Employee (TTM)$0
Tangible BV / Share (Quarterly)$-0.12
P/S Ratio (Annual)108.01x
Asset Turnover (Annual)0.01x
52-Week High$29.98
Operating Margin (5Y Avg)-511.36%
EPS Excl Extra (Annual)$0.64
CapEx CAGR (5Y)-15.67%
Tangible BV CAGR (5Y)-29.22%
26-Week Price Return-53.50%
Quick Ratio (Annual)2.40x
13-Week Price Return-44.71%
Total Debt / Equity (Annual)0.00x
Current Ratio (Quarterly)2.56x
Enterprise Value$39.456
Revenue / Share Growth (5Y)-35.44%
Asset Turnover (TTM)0.01x
Book Value / Share Growth (5Y)25.33%
Revenue / Employee (Annual)$0
Pretax Margin (Annual)721.93%
Cash / Share (Annual)$4.79
3-Month Return Std Dev101.49%
Net Income / Employee (TTM)$0
ROE (Last FY)12.88%
Net Interest Coverage (Annual)-12.95x
EPS Basic Excl Extra (Annual)$0.64
P/FCF (TTM)2.93x
Receivables Turnover (TTM)30.88x
EV / Free Cash Flow (TTM)45.61x
Total Debt / Equity (Quarterly)0.00x
EPS Incl Extra (TTM)$0.75
ROI (TTM)13.30%
P/S Ratio (TTM)108.01x
Pretax Margin (5Y Avg)-29.07%
Revenue / Share (Annual)$0.09
Tangible BV / Share (Annual)$0.09
Forward P/E33.91x
Price vs S&P 500 (52W)-23.97%
P/E Ratio (TTM)14.96x
Year-to-Date Return-40.26%
5-Day Price Return3.61%
EPS Normalized (Annual)$0.64
ROA (5Y Avg)-23.54%
Net Profit Margin (Annual)721.93%
Month-to-Date Return0.23%
Cash Flow / Share (TTM)$-1.06
EBITD / Share (Annual)$0.86
Operating Margin (Annual)-1683.90%
LT Debt / Equity (Annual)0.00x
P/CF (TTM)76.30x
ROI (5Y Avg)-95.46%
P/E Excl Extra (TTM)14.96x
LT Debt / Equity (Quarterly)0.00x
EPS Basic Excl Extra (TTM)$0.75
P/B Ratio (Annual)3.04x
Pretax Margin (TTM)-903.80%
Book Value / Share (Annual)$4.63
Price vs S&P 500 (13W)-47.58%
Beta0.24x
P/FCF (Annual)98.52x
Revenue / Share (TTM)$0.09
ROE (TTM)13.30%
52-Week Low$6.53
Analyst Recommendations
Jan 2026
Feb 2026
Mar 2026
Apr 2026
3.89
3.89
3.89
4.14
Industry Peers — Pharmaceuticals(309)
| Symbol | P/S Ratio (TTM) | Revenue Growth TTM (YoY) | Gross Margin (TTM) | EPS Growth (5Y) | Price |
|---|---|---|---|---|---|
MCRBSeres Therapeutics, Inc. | 108.01x | — | — | — | $8.89 |
LLYEli Lilly & Co. | 13.44x | 44.70% | 83.04% | 27.59% | $927.03 |
JNJJohnson & Johnson | 5.85x | 7.87% | 67.95% | 14.90% | $234.18 |
ABBVABBVIE INC. | 6.03x | 8.57% | 71.62% | -2.88% | $208.38 |
MRKMerck & Co., Inc. | 4.53x | 1.31% | 78.55% | 21.23% | $119.07 |
AZNAstraZeneca PLC | 5.30x | 8.63% | 81.31% | 21.88% | $204.80 |
NVSNovartis AG | 4.87x | 8.91% | 75.82% | 15.26% | $151.97 |
NVONovo-Nordisk A/S | 3.70x | 6.43% | 80.98% | 20.66% | $40.52 |
ABTAbbott Laboratories | 3.74x | 6.59% | 56.50% | 8.20% | $96.81 |
PFEPfizer Inc. | 2.51x | -1.64% | 75.81% | -3.51% | $27.56 |
BMYBristol-Myers Squibb Co. | 2.55x | -0.22% | 72.63% | — | $60.17 |
About
Seres Therapeutics is a microbiome therapeutics company developing biological drugs designed to restore and repair the function of dysbiotic microbiomes. The company's lead product, SER-109, is designed to prevent recurrent Clostridium difficile infection (CDI), a serious colon infection. The company is also advancing a pipeline of additional candidates including SER-262, SER-287, and SER-401.